Atsena Therapeutics

Co-founder and Advisor Sanford Boye is presenting today at the 45th Annual Meeting of the American College of Toxicology (ACT)! His presentation will spotlight key insights in preclinical toxicology for #ocular gene therapies, including the development of our best-in-class #genetherapy candidate, ATSN-201, designed to treat X-linked retinoschisis (#XLRS). ? Follow #ACTOX2024 for more updates! ? https://lnkd.in/e5653jME ?

Our Senior Medical Director, Dr. Dan Yoon, represented Atsena during the Association for Research in Vision and Ophthalmology (ARVO) Frontiers in Ocular Gene Therapy Research?virtual conference! The conference gathered industry experts and innovators to discuss the latest #ocular innovations and treatments. ? Dr. Yoon shared insights from the 12-month safety and efficacy data of our first-in-class, investigational ocular #GeneTherapy, ATSN-101, to treat patients with Leber congenital?amaurosis caused by biallelic mutations in GUCY2D (#LCA1).?

Nippon Shinyaku and Atsena Therapeutics collaborate on ATSN-101 Read the article: https://lnkd.in/eT7y5G7j

?? Atsena Therapeutics & Nippon Shinyaku Partner to Advance Gene Therapy for LCA1 Atsena Therapeutics and Nippon Shinyaku have entered an exclusive agreement to develop and commercialize ATSN-101, a first-of-its-kind gene therapy for Leber congenital amaurosis type 1 (LCA1), in the U.S. and Japan. This partnership brings ATSN-101 closer to becoming a transformative treatment for patients with LCA1, a rare retinal disease with no current therapies. “This agreement accelerates ATSN-101’s development and validates Atsena’s pioneering technology,” said Atsena CEO Patrick Ritschel. Nippon Shinyaku President Toru Nakai added, “We are excited to partner with Atsena and contribute to their groundbreaking science.” ??Discover how this partnership is advancing gene therapy for retinal disease: https://lnkd.in/gQ5BZge4 #Collaboration #GeneTherapy #EyeDisease #Ophthalmology #Innovation

Nippon Shinyaku, a pharmaceutical company based in Kyoto, Japan, and Atsena Therapeutics, a developer of gene therapies for retinal diseases in Durham, North Carolina, have entered into a license agreement for the commercialization of ATSN-101, an emerging gene therapy for Leber congenital amaurosis 1 (LCA1) which is caused by mutations in the gene GUCY2D. Read more at: https://bit.ly/3YO1mRT

Nippon Shinyaku and Atsena Therapeutics have entered into an exclusive strategic collaboration for ATSN-101 in the U.S. and Japan. Read more at: https://bit.ly/4eoDH0c

We’re excited to share the news that our parent company Nippon Shinyaku has entered into an exclusive license agreement with Atsena Therapeutics to commercialize its ATSN-101 therapy in the United States and Japan! ATSN-101 is a first-in-class, investigational #genetherapy for the treatment of Leber congenital amaurosis (LCA1). LCA1 is a rare eye disease that disrupts the function of the retina and results in early and severe vision impairment or blindness. Read more in our press release: https://ow.ly/tFQx50U6nK2 #opthalmology #raredisease #lebers

#NipponShinyaku and Atsena Therapeutics Join Forces to Commercialize ATSN-101 Across the US and Japan #nipponshinyaku #atsenatherapeutics #atsn101 #lebercongenitalamaurosis #pharma #pharmashots

???Exciting News: Atsena Therapeutics Announces?Exclusive Strategic Collaboration with Nippon Shinyaku for ATSN-101 in the U.S. and Japan! ?? ? We’re thrilled to share that we have entered into an exclusive license agreement with?Nippon Shinyaku?to commercialize and develop our first-in-class, investigational ocular #GeneTherapy ATSN-101 to treat Leber congenital amaurosis caused by biallelic mutations in?GUCY2D?(LCA1).?This partnership marks a significant step forward in our mission to bring life-changing therapies to those affected by #InheritedRetinalDiseases. ? Together, we aim to push the boundaries of what’s possible in ocular gene therapy, advancing multiple clinical programs and our novel technologies. We anticipate this will be the first?of many ocular gene therapy treatments from our clinical portfolio to come!????? ? Read the full press release here: https://lnkd.in/ejwUjFAG Visual description: The image features a portrait of Patrick Ritschel, Chief Executive Officer of Atsena Therapeutics, on the left side. On the right side, against a gradient background that transitions from purple?at the top to blue at the bottom, with a dotted texture, there is white text displaying a quote from Mr. Ritschel: ? ?“This collaboration creates a path to accelerate the development of ATSN-101 and validates Atsena’s pioneering technology and development capabilities. We look forward to working with Nippon?Shinyaku as we advance ATSN-101 into a pivotal trial and potential approval to provide an innovative solution to patients and families affected by LCA1 around the world.” ? ?The Atsena Therapeutics logo is In the bottom right corner.

We were honored to participate in the impactful Foundation Fighting Blindness’ Northeast Vision Seminar on #InheritedRetinalDiseases (IRDs). This special event brought together experts including our Founder and CSO, Shannon Boye, PhD, who shared insights on the latest advancements and ongoing challenges in ocular #GeneTherapy research. ? Attendees also took part in an unforgettable fundraising event,?Dinner in the Dark, hosted by Hope in Focus. This unique culinary experience had guests dine blindfolded to raise awareness and support for those affected by Leber congenital amaurosis and other rare IRDs. ? Visual description: ? A collage with images highlighting Atsena Therapeutics' participation in the "Dinner in the Dark" event. The collage includes: -Attendees holding signs with phrases like "We see a cure for blindness" and ---"The zebra is the international symbol of #raredisease" in front of a horse-themed backdrop, some with a guest dressed as a zebra. -The "Dinner in the Dark: A Unique Sensory Experience" event program and eye mask. -Braille menu that was part of the sensory experience. -A group photo with four people, including Atsena Therapeutics representatives, in formal attire posing in front of an event banner with sponsor logos, including Atsena’s.